Navigation Links
REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis
Date:9/23/2011

the past 17 years and through commercial experience with more than 1.5 million patients treated worldwide.

In the U.S., REMICADE® is approved for the following indications:

  • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA, when administered in combination with methotrexate.  
  • Reducing signs and symptoms in patients with active ankylosing spondylitis.
  • Reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.  
  • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn's disease.  
  • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
  • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis.  
  • Treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

REMICADE® is unique among available anti-TNF-alpha biologic therapies.  It is the only anti-TNF-alpha biologic administered directly by caregivers in the clinic or office setting.  REMICADE® is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6.  As a result, REMICADE® patients may require as few
'/>"/>

SOURCE Janssen Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
2. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
3. FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... and six months ended June 30, 2015 and updated ... its earnings conference call this morning, August 4, 2015, ... can join the call by dialing (855) 582-8078. The ... , Year-to-date net revenues of $38.3 million, an increase ...
(Date:8/4/2015)...  Ironshore Pharmaceuticals & Development, Inc. ("Ironshore") has ... specializing in personalized medicine, to participate in the ... evaluate the safety and efficacy of HLD-200, a ... (ADHD). This is Restore,s second clinical trial program ... with Ironshore in 2014 and continues to work ...
(Date:8/3/2015)... Utah , Aug. 3, 2015  BC Technical, the ... acquired Ohio Valley Medical Systems, one of the largest ...  The addition of Ohio Valley Medical Systems allows BC ... include Hitachi MRI.   "We couldn,t be ... , President and CEO of BC Technical. "The Ohio ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2BC Technical Acquires Ohio Valley Medical Systems 2
... 2012  Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the ... a company overview at Citi,s 2012 Global Health Care Conference ... the Waldorf Astoria in New York City. A ... the "Investors & Media" section of the Company,s Web site, ...
... Feb. 21, 2012   Enanta Pharmaceuticals, Inc. , ... best-in-class small molecule drugs in the infectious disease ... an exclusive collaboration and license agreement with Novartis ... its lead development candidate, EDP-239, from its NS5A ...
Cached Medicine Technology:Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV 2Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV 3
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is ... health conditions, pictures and medical art can be essential. StayWell, a health solutions company, ... Krames Patient Education solutions have been used by physicians and other health care providers ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... today announced that Bruce McCalley joins its executive leadership team as Senior Vice ... sales success at technology companies and expanding global markets with a special emphasis ...
(Date:8/4/2015)... Denver, CO (PRWEB) , ... August 04, 2015 ... ... for skilled nursing homes and other long-term care facilities, today announced details of ... (QAPI) for nursing homes and centers. , Providigm’s QAPI Accreditation program , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Data2Life , a Tel ... to provide pharmaceutical and healthcare organizations with advanced intelligence on drug effects. The ... regulatory filings (including the FDA and HealthCanada), social media and anonymized clinical electronic ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers are considering ... is increasingly influential in their choice of practitioner, according to new survey data ... on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments and ...
Breaking Medicine News(10 mins):Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... A unique global conference,focusing on the future ... - 10,2009. The HealthQuake Summit will present an ... and explore the ongoing and future seismic,"tremors" in ... policy, and,science/technology that will make the industry virtually ...
... for Passover, ATLANTA, April 14 As Americans ... Centers for Disease Control,and Prevention advises all travelers to ... a measles outbreak in Israel., Since September, more ... with about 700 cases in the cities of Jerusalem ...
... of needing to start treatment , , MONDAY, April 14 ... antioxidant urate in their blood appear to develop the symptoms ... a new report says. , The findings, published in the ... early laboratory studies about urate,s protective qualities and offer hope ...
... treated , , MONDAY, April 14 (HealthDay News) -- People ... headaches than those with normal blood pressure, a new ... the new research does not mean those with hypertension ... pressure medications. , The stiff arteries that are associated ...
... arthritis (RA) sufferers, the Medicare Prescription Drug Improvement ... better disease management with biologic drugs. Prior to ... of the tumor necrosis factor (TNF) inhibitors, ... brand name, Remicade. Since the MMA, most Medicare ...
... BMW NA, Henry Ford Health System, Kraft Foods ... VitalSpring Award-Winning,Health Benefits Solution to Drive Industry Standards ... HR and Benefits Executives is Scheduled for,April 22nd, ... for Wellness ROI,Inc. announced today that it has ...
Cached Medicine News:Health News:CDC Urges Travelers to Israel to Protect Themselves from Measles 2Health News:Elevated Urate Levels May Slow Parkinson's in Men 2Health News:High Blood Pressure May Be Buffer Against Headaches 2Health News:High Blood Pressure May Be Buffer Against Headaches 3Health News:Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients 2Health News:Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients 3Health News:Alliance for Wellness ROI, Inc. Selects VitalSpring as Exclusive Technology Partner 2Health News:Alliance for Wellness ROI, Inc. Selects VitalSpring as Exclusive Technology Partner 3
... Healthcare is known as ... analysis programs for every ... device. With advanced programs ... and ACI-TIPI, GE can ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... Guidant INSIGNIA Ultra pacing ... easy-to-use features for simplified ... patient safety. All INSIGNIA ... using the ZOOM Programming ...
... SDX model 1688 and model 1488 active-fixation ... pacing leads, offering the unsurpassed handling advantages, ... Medical's line of active-fixation leads. Implantable with ... diameter of the Tendril SDX lead is ...
Medicine Products: